Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective

Breast Cancer Research and Treatment

Volumn 114, Issue 3, 2009, Pages 537-547

  Schegerin, Marc ^a,b,c   Tosteson, Anna N A ^b   Kaufman, Peter A ^b   Paulsen, Keith D ^c   Pogue, Brian W ^c  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH COLLEGE   (United States)

Author keywords

Breast cancer; Chemotherapy; Cost; Cost effectiveness; Imaging; Model; Near infrared; Neoadjuvant; Prognostic; Spectroscopy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; FEMALE; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; FEMALE; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, INFRARED;

EID: 61449249877     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0025-2     Document Type: Article

References (22)

1. L Mauriac M Debled G MacGrogan 2005 When will more useful predictive factors be ready for use? Breast 14 6 617 623
2. H Charfare S Limongelli AD Purushotham 2005 Neoadjuvant chemotherapy in breast cancer Br J Surg 92 1 14 23
3. YC Chang CS Huang YJ Liu JH Chen YS Lu WY Tseng 2004 Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI Phys Med Biol 49 16 3593 3602
4. MS Kwong GG Chung LJ Horvath BA Ward AD Hsu D Carter F Tavassoli B Haffty BA Burtness 2006 Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer Cancer J 12 3 212 221
5. F Denis AV Desbiez-Bourcier C Chapiron F Arbion G Body L Brunereau 2004 Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer Eur J Surg Oncol 30 10 1069 1076
6. M Tozaki S Uno T Kobayashi K Aiba K Yoshida H Takeyama H Shioya I Tabei Y Toriumi M Suzuki M Kawakami K Fukuda 2004 Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI Radiat Med 22 4 246 253
7. M Golshan BB Fung E Wiley J Wolfman A Rademaker M Morrow 2004 Prediction of breast cancer size by ultrasound, mammography and core biopsy Breast 13 4 265 271
8. C Marshall J Eremin M El-Sheemy O Eremin PA Griffiths 2005 Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99 m) Tc-Sestamibi uptake Nucl Med Commun 26 1 9 15
9. SK Apple F Suthar 2006 How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy? Breast 15 3 370 376
10. EL Rosen KL Blackwell JA Baker MS Soo RC Bentley D Yu TV Samulski MW Dewhirst 2003 Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy AJR Am J Roentgenol 181 5 1275 1282
11. RM Warren LG Bobrow HM Earl PD Britton D Gopalan AD Purushotham GC Wishart JR Benson W Hollingworth 2004 Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 90 7 1349 1360
12. MA Roubidoux GL LeCarpentier JB Fowlkes B Bartz D Pai SP Gordon AF Schott TD Johnson PL Carson 2005 Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy J Ultrasound Med 24 7 885 895
13. LK Dunnwald JR Gralow GK Ellis RB Livingston HM Linden TJ Lawton WE Barlow EK Schubert DA Mankoff 2005 Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival Cancer 103 4 680 688
14. YC Cheung SC Chen MY Su LC See S Hsueh HK Chang YC Lin CS Tsai 2003 Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI Breast Cancer Res Treat 78 1 51 58
15. DJ Manton A Chaturvedi A Hubbard MJ Lind M Lowry A Maraveyas MD Pickles DJ Tozer LW Turnbull 2006 Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy Br J Cancer 94 3 427 435
16. A Cerussi D Hsiang N Shah R Mehta A Durkin J Butler BJ Tromberg 2007 Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy Proc Natl Acad Sci USA 104 10 4014 4019
17. R Choe A Corlu K Lee T Durduran SD Konecky M Grosicka-Koptyra SR Arridge BJ Czerniecki DL Fraker A DeMichele B Chance MA Rosen AG Yodh 2005 Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI Med Phys 32 4 1128 1139
18. BJ Tromberg A Cerussi N Shah M Compton A Durkin D Hsiang J Butler R Mehta 2005 Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy Breast Cancer Res 7 6 279 285
19. HM Kuerer KK Hunt LA Newman MI Ross FC Ames SE Singletary 2000 Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues J Am Coll Surg 190 3 350 363
20. Arias E (2004) United States Life Tables 2003. National vital statistics reports, vol 53. U. S. Department of Health and Human Services Centers for Disease Control and Prevention
21. A Laupacis D Feeny AS Detsky PX Tugwell 1992 How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Can Med Assoc J 146 473 481
22. IC Smith SD Heys AW Hutcheon ID Miller S Payne FJ Gilbert AK Ah-See O Eremin LG Walker TK Sarkar SP Eggleton KN Ogston 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456 1466